Identification of drugs associated with reduced severity of COVID-19 – a case-control study in a large population
| Autor: | Eyal Schiff, Sanju Sinha, Eytan Ruppin, Alejandro A. Schäffer, Ariel Israel, Ameer Tal, Gil Lavie, Kuoyuan Cheng, Assi Cicurel, Ilan Feldhamer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Ubiquinone retrospective study Severity of Illness Index Cohort Studies 0302 clinical medicine Odds Ratio Biology (General) Rosuvastatin Calcium Vitamin D Prospective cohort study Aged 80 and over Microbiology and Infectious Disease education.field_of_study General Neuroscience General Medicine Middle Aged Hospitalization Cohort Medicine disease severity Female Research Article Human medicine.drug Cohort study Adult medicine.medical_specialty Adolescent QH301-705.5 Science Population Antiviral Agents Article General Biochemistry Genetics and Molecular Biology Young Adult 03 medical and health sciences Ezetimibe Internal medicine Severity of illness medicine Humans Rosuvastatin education Aged General Immunology and Microbiology SARS-CoV-2 business.industry Case-control study COVID-19 Retrospective cohort study Odds ratio Confidence interval COVID-19 Drug Treatment Epidemiology and Global Health 030104 developmental biology Case-Control Studies business 030217 neurology & neurosurgery |
| Zdroj: | medRxiv article-version (status) pre article-version (number) 2 eLife eLife, Vol 10 (2021) |
| ISSN: | 2050-084X |
| DOI: | 10.7554/elife.68165 |
| Popis: | Background:Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted a large population study in Clalit Health Services (CHS), the largest healthcare provider in Israel, insuring over 4.7 million members.Methods:Two case-control matched cohorts were assembled to assess which medications, acquired in the last month, decreased the risk of COVID-19 hospitalization. Case patients were adults aged 18 to 95 hospitalized for COVID-19. In the first cohort, five control patients, from the general population, were matched to each case (n=6202); in the second cohort, two non-hospitalized SARS-CoV-2 positive control patients were matched to each case (n=6919). The outcome measures for a medication were: odds ratio (OR) for hospitalization, 95% confidence interval (CI), and the p-value, using Fisher’s exact test. False discovery rate was used to adjust for multiple testing.Results:Medications associated with most significantly reduced odds for COVID-19 hospitalization include: ubiquinone (OR=0.185, 95% CI [0.058 to 0.458], pConclusions:Ubiquinone, ezetimibe, and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings point to a promising protective effect which should be further investigated in controlled, prospective studies.Funding:This research was supported in part by the Intramural Research Program of the National Institutes of Health, NCI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|